Carysil Limited has submitted its quarterly compliance certificate to stock exchanges for the quarter ended March 31, 2026, fulfilling regulatory requirements under SEBI guidelines.

Regulatory Compliance Filing

The company filed a certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 on April 08, 2026. This mandatory quarterly submission was made to both BSE Limited and National Stock Exchange of India Limited.

Certificate Confirmation

Bigshare Services Private Limited, serving as the company's Registrar and Share Transfer Agent, issued the compliance certificate confirming adherence to dematerialization procedures. The certificate validates that securities received from depository participants for dematerialization up to March 31, 2026 were properly processed.

Key compliance confirmations include:

• Securities received for dematerialization were confirmed to depositories within required timeframes
• Security certificates were mutilated and cancelled after due verification
• Depository names were substituted in the register of members as registered owners within 15 days
• All securities remain listed on stock exchanges where previously issued securities are traded

Corporate Information

The filing was signed by Reena Shah, Company Secretary and Compliance Officer, demonstrating proper corporate governance procedures. The company maintains its head office at Survey No. 312, Navagam, Vartej, Bhavnagar, Gujarat, with registered office in Mumbai.

This quarterly compliance certificate represents standard regulatory practice, ensuring transparency in securities handling and maintaining investor confidence through proper adherence to SEBI guidelines.

Carysil Limited has formally announced the completion of Dr. Sonal Ambani's second term as Independent Director, effective March 31, 2026. The company disclosed this information to stock exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Director Term Completion Details

Dr. Sonal Ambani (DIN: 02404841) will cease to be an Independent Director of the company at the close of business hours on March 31, 2026. This marks the completion of her second and final consecutive term as an Independent Director, in accordance with the applicable provisions of the Companies Act, 2013 and SEBI Listing Regulations.

Committee Memberships

With the completion of her directorship, Dr. Ambani will also cease to be a member of multiple board committees. Her committee responsibilities included:

• Audit Committee – Member
• Nomination and Remuneration Committee – Member
• Stakeholders Relationship Committee – Member
• Corporate Social Responsibility Committee – Member
• Finance and Budget Committee – Member

Regulatory Compliance

The company has submitted the required disclosure under Regulation 30 read with Schedule III of the SEBI Listing Regulations. Carysil received a formal letter from Dr. Sonal Ambani regarding the completion of her term, confirming that her cessation is solely due to the completion of her second and final term as an Independent Director with no other material reasons.

Board Acknowledgment

The Board of Directors has placed on record its sincere appreciation and gratitude for Dr. Ambani's valuable guidance and contribution during her tenure as an Independent Director. In her communication to the company, Dr. Ambani expressed gratitude for the opportunity to serve as an Independent Director for two consecutive terms and thanked the Board for the support and cooperation extended during her tenure.

The company has requested the stock exchanges to treat this disclosure as compliance with the applicable provisions of the SEBI Listing Regulations and will complete all necessary formalities, including required filings and intimations with relevant regulatory authorities.